With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|WIP1 Modulates Responsiveness of MB to Genotoxic Stress.||Aflac Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta / Robert Craig Castellino, MD||Young Investigator Grants||2006||Georgia|
|CHOA Experimental Therapy Pediatric Oncology Research.||Aflac Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta / Howard Katzenstein, MD||Phase I/II Infrastructure Grants||2006||Georgia|
|Parallel sequencing to identify the causes of childhood cancer.||Baylor College of Medicine / Sharon Plon, MD, PhD||Innovation Grants||2006||Texas|
|Building a Texas-based center for neuroblastoma clinical research.||Baylor College of Medicine / Heidi Russell, MD||Phase I/II Infrastructure Grants||2006||Texas|
|Expanding Access to New Agents for Cancer Treatment.||Children's Hospital Colorado / Lia Gore, MD||Phase I/II Infrastructure Grants||2006||Colorado|
|Assess the activity of ABT-737 as a single agent against neuroblastoma cell lines grown in cell culture||Children's Hospital Los Angeles / Theresa Harned, MD||Young Investigator Grants||2006||California|
|New Approaches to Neuroblastoma Therapy (NANT) Consortium||Children's Hospital Los Angeles / Robert Seeger, MD||Phase I/II Infrastructure Grants||2006||California|
|Research Institute at Nationwide Children's Hospital / Mary Beth Ross, MD/PhD||Young Investigator Grants||2006||Ohio|
|Tyrosine Kinase Mutation Discovery in Neuroblastoma.||Dana-Farber Cancer Institute / Matthew Meyerson, MD, PhD||Innovation Grants||2006||Massachusetts|
|Anti-Angiogenic (Metronomic) Chemotherapy in Children with Poor Prognosis.||Dana-Farber Cancer Institute / Mark Kieran, MD, PhD||Innovation Grants||2006||Massachusetts|